Capivasertib for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 27 Nov 2025: Trial started, NCT07281833
  2. 15 Dec 2025: Trial registered, NCT07281833

The trials

NCT07281833: Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

State
Under way
Phase
Phase 3
People
250 planned
Started
27 Nov 2025
Primary completion
Mar 2030
Arms
Capivasertib
Results
None posted
  1. 27 Nov 2025: Trial started
  2. 15 Dec 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Truqap.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.